Equities Analysts Set Expectations for Aprea Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:APRE)

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities research analysts at Wedbush issued their Q1 2025 earnings estimates for Aprea Therapeutics in a research report issued on Tuesday, March 26th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.00) per share for the quarter. Wedbush currently has a “Outperform” rating and a $11.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Aprea Therapeutics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.31) EPS and FY2028 earnings at $0.81 EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a report on Tuesday.

Aprea Therapeutics Stock Performance

Shares of NASDAQ:APRE opened at $6.07 on Thursday. The company has a fifty day simple moving average of $6.36 and a 200 day simple moving average of $4.99. Aprea Therapeutics has a 12-month low of $2.78 and a 12-month high of $8.85.

Insiders Place Their Bets

In related news, Director Bernd R. Seizinger acquired 6,860 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were purchased at an average price of $7.29 per share, for a total transaction of $50,009.40. Following the acquisition, the director now owns 33,685 shares in the company, valued at $245,563.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have acquired 9,870 shares of company stock worth $71,952. 20.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aprea Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its stake in shares of Aprea Therapeutics by 5.7% in the first quarter. Renaissance Technologies LLC now owns 297,900 shares of the company’s stock valued at $554,000 after purchasing an additional 15,977 shares in the last quarter. Royal Bank of Canada grew its position in Aprea Therapeutics by 13,788.0% in the fourth quarter. Royal Bank of Canada now owns 44,025 shares of the company’s stock valued at $207,000 after acquiring an additional 43,708 shares during the period. Vanguard Group Inc. grew its holdings in shares of Aprea Therapeutics by 26.9% during the fourth quarter. Vanguard Group Inc. now owns 34,688 shares of the company’s stock worth $163,000 after purchasing an additional 7,347 shares during the last quarter. Geode Capital Management LLC bought a new stake in shares of Aprea Therapeutics during the second quarter worth $74,000. Finally, Jane Street Group LLC bought a new stake in shares of Aprea Therapeutics during the second quarter worth $54,000. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.